tbuckley/cabot-search huggingface dataset:
DNR in the OR
Authors: David M. Rothenberg
Journal: JAMA (1992)

<h3>To the Editor.</h3> —While encouraging flexibility in DNR policies for the OR, both the article by Walker<sup>1</sup>and the accompanying editorial by Youngner et al<sup>2</sup>failed to mention an important aspect of such policies—the patient's option to have life support discontinued when it is acknowledged to be death-delaying rather than life-prolonging. Our experience suggests that most terminally ill patients request DNR orders not out of a desire to die, but because they do not want to be kept alive on life support with little or no hope of recovery. In this respect, we believe that few patients with DNR orders who consent to operative procedures expect to die as a result of their surgery. In recognition of this, as part of the preoperative informed consent process, patients should be given the option to have intubation and/or vasopressors instituted when needed during surgery with the guarantee that they will
Psychotherapie. Charakterlehre, Psychoanalyse, Hypnose, Psychagogik.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The sociopolitics of contraception
Authors: Elizabeth Rasche González
Journal: JAMA (1980)

One of the earliest clinical trials of a contraceptive vaccine took place in India. Such research is disturbing to activists who charge that Third World people are "guinea pigs" for contraceptive experiments that would not be performed on white Americans. That contraceptives are frequently tested in developing countries cannot be denied. Contraceptive research is generally associated with the stated political goal of improving economic conditions over the long term in heavily populated nations and freeing the women of those nations to do more with their lives than bear children from puberty through menopause (<i>Int Fam Plann Perspect</i>6:47, 1980). Many contraceptive researchers are themselves citizens of developing countries. Those who are not export their technologies only at the behest of foreign governments and implement those technologies in close cooperation with family planning specialists who are natives of the countries. Such arrangements do not satisfy the critics, who say that no matter
Left atrial myxoma: diagnosis, treatment, and cytological observations
Authors: D. J. Coltart
Journal: JAMA (1975)

A patient first seen with cardiac cachexia was found to have a large left atrial myxoma. The diagnosis was first suggested by echocardiographic examination. Cure was achieved by surgery. Light and electron microscopic studies indicate a multipotential mesenchymal cell origin of myxomata. (<i>JAMA</i>234:950-953, 1975)
Dietary fiber for the diabetic
Authors: S. Vaisrub
Journal: JAMA (1978)

Fiber, the touted prophylaxis for a host of disorders<sup>1</sup>— hemorrhoids, hiatus hernia, varicose veins, gallbladder disease, appendicitis, diverticulitis, colon cancer, diabetes, ischemic heart disease—has had a rough time living up to the claims made in its behalf. Until recently only one claim—and this by no means a new one—has remained uncontested. Fiber is great for constipation. Recent studies suggest that fiber may also prove useful in controlling hyperglycemia. Douglass<sup>2</sup>noted a decrease in insulin requirements of two diabetic patients when they increased the amount of raw, unprocessed, fiber-rich foods in their diets. Jenkins et al<sup>3</sup>observed a drop in postprandial plasma glucose and insulin levels in eight insulin-independent and three insulin-dependent diabetic subjects after two fiber products, pectin and guar, had been added to the standardized meals. Kiehm et al<sup>4</sup>reported a lowering of fasting plasma glucose levels and a diminished need of sulfonylureas or
Book Review The Heart, Arteries and Veins Seventh edition. Edited by J. Willis Hurst, with Robert C. Schlant, Charles E. Rackley, Edmund H. Sonnenblick, and Nanette Kass. 2348 pp., illustrated. New York, McGraw-Hill, 1990. $99 (single volume); $115 (two volumes).
Journal: New England Journal of Medicine (1990)
Acute Effects of Inhalable Particles on the Frog Palate Mucociliary Epithelium
Authors: Mariangela Macchione, Alexandre P. Oliveira, Christina T. Gallafrio, Fabio P. Muchao, Marcos T. Obara, Eliane T. Guimaraes, Paulo Artaxo, Malcolm King, Geraldo Lorenzi-Filho, Virginia C. B. Junqueira, Paulo H. N. Saldiva
Journal: Environmental Health Perspectives (1999)

This work was designed to evaluate the toxicity of inhalable particles [less than/equal to] 10 microm in aerodynamic diameter (PM(10)) collected from the urban air in São Paulo, Brazil, to the mucociliary apparatus using the frog palate preparation. Seven groups of frog palates were immersed in different concentrations of PM(10) diluted in Ringer's solution during 120 min: 0 (control, n = 31); 50 (n = 10); 100 (n = 9); 500 (n = 28); 1,000 (n = 10); 5,000 (n = 11); and 10,000 microg/m(3) (n = 10). Mucociliary transport and transepithelial potential difference were determined at 0, 30, 60, and 120 min exposure. Additional groups (control and 500 microg/m(3)) were studied by means of morphometric analyses (quantification of the amount of intraepithelial and surface mucins), measurement of cilia beat frequency, and quantification of total glutathione. Mucociliary transport and transepithelial potential difference were significantly decreased at higher concentrations of PM(10) (p = 0.03 and p = 0.02, respectively). Exposure to PM(10) also elicited a significant decrease of total glutathione (p = 0. 003) and depletion of neutral intraepithelial mucins (p = 0.0461). These results show that PM(10) can promote significant alterations in ciliated epithelium in vitro.
<i>QuickStats:</i> Number of Natural Heat-Related Deaths,* by Sex and Age Group — National Vital Statistics System, United States, 2018
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

No. of deathsAge group (yrs) Male Female * Deaths associated with exposure to natural heat, as the underlying and contributing causes of death, are coded as X30 and T67, excluding code W92 (exposure to excessive heat of manmade origin) according to the International Classification of Diseases, Tenth Revision, for a total of 726 deaths among males and 282 among females.In 2018, natural heat exposure was associated with 726 deaths among males and 282 deaths among females.Among males, the highest number of heat-related deaths was for those aged 55-64 years (150) and among females for those aged 65-74 years (58).The lowest numbers were for males (four) and females (two) aged 5-14 years.Approximately 72% of heat-related deaths were among males.
Narrative Medicine
Authors: Roy M. Poses
Journal: Annals of Internal Medicine (2001)

Letters20 November 2001Narrative MedicineRoy M. Poses, MDRoy M. Poses, MDBrown University School of MedicineL; Pawtucket, RI 02860 (Poses)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-10-200111200-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Rita Charon bases her promotion of narrative medicine on arguments that “sickness and healing are, in part, narrative acts,” and that “narrative turns” are increasingly popular in the humanities (1). Charon never explains how sickness is an “act” and never defines “narrative turns” or “narrative competence.” Nonetheless, she has previously argued that “narrative theory [leads to] new approaches to understanding … in a postmodern world” (2). What she seems to be advocating is the medical application of what has variously been called deconstructionism, poststructuralism, critical literary theory, or postmodernism. Yet she provides no evidence or logical argument ...References1. Charon R. Narrative medicine: form, function, and ethics. Ann Intern Med. 2001;134:83-7. [PMID: 11187429] LinkGoogle Scholar2. Charon R, Banks JT, Connelly JE, Hawkins AH, Hunter KM, Jones AH, et al . Literature and medicine: contributions to clinical practice. Ann Intern Med. 1995;122:599-606. [PMID: 7887555] LinkGoogle Scholar3. Gross PR, Levitt N. Higher Superstition: the Academic Left and Its Quarrels with Science. Baltimore: Johns Hopkins Univ Pr; 1994:72. Google Scholar4. Farber DA, Sherry S. Beyond All Reason: the Radical Assault on Truth in American Law. New York: Oxford Univ Pr; 1997:13. Google Scholar5. Ellis JM. Literature Lost: Social Agendas and the Corruption of the Humanities. New Haven, CT: Yale Univ Pr; 1997:31. Google Scholar Author, Article, and Disclosure InformationAuthors: Roy M. Poses, MDAffiliations: Brown University School of MedicineL; Pawtucket, RI 02860 (Poses) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNarrative Medicine: Form, Function, and Ethics Rita Charon Narrative Medicine Rita Charon Metrics Cited byPain narratives and narrative practitioners: a way of working ’in-relation’ with children experiencing pain 20 November 2001Volume 135, Issue 10Page: 929-930KeywordsGratitude ePublished: 20 November 2001 Issue Published: 20 November 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
UNDERGROUND TRANSIT AND PUBLIC HEALTH.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Second Multiple Discipline Research Forum of the American Medical Association
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Authors: Medtcal Medisecra Westrand
Journal: BMJ (1925)

The members of the party (limited to 200 in number) will travel by special t-ain in Italy and will be accommnodated at flrst-class hotels.A limited number of places in the tour are reserved for members of the families of participants.Italian doctors, spealking fluent English, accompany the tour an(d assist in the miiedical conference held at each centre.The charge for tha tour, including cost of travel from lMilan to Rome, railway and hotel expenses, will be lire 1,600 (about £15).
Allergy abstracts
Authors: Murray Albert, N Brooklyn, Eugene Bridgeport, Ohio Monroe, Coleman Stamfotd, Cow& Siegel Brooklyn, N Eloise, Kailin Seqzeim, Wa8h David Stein, Spring Valley, Jerome Shapiro, Neil Goldman, Santa Clara, Calif Ossinhg, N Sheldon Berger Freehold
Journal: Journal of Allergy and Clinical Immunology (1975)
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
Authors: Owen A. O'Connor, Barbara Pro, Tim Illidge, Lorenz H. Trumper, Emily K. Larsen, Dana A. Kennedy
Journal: Journal of Clinical Oncology (2014)

TPS8612 Background: MTCL including systemic anaplastic large cell lymphoma (sALCL) are aggressive neoplasms. Anthracycline-based multiagent chemotherapy regimens have demonstrated response rates ranging from 76 to 88%. Five-year overall survival rates range from 12 to 49% depending on the histologic subtype. Brentuximab vedotin is an antibody drug conjugate that has shown efficacy in a pivotal phase 2 study as a single agent in relapsed sALCL (Pro et al., J Clin Oncol, 2012) and evidence of clinical activity in combination with CHP in the frontline treatment of MTCL including sALCL in a phase 1 study (Fanale et al., ASH 2012). Methods: This randomized, double-blind, placebo-controlled, multicenter, phase 3 study (NCT01777152) is evaluating the safety and efficacy of 1.8 mg/kg brentuximab vedotin with CHP (A+CHP) vs CHOP for frontline treatment of CD30+ MTCL. Pts must have FDG-avid disease by PET and measureable disease of at least 1.5 cm by CT. Approximately 300 pts will be randomized 1:1 to receive A+CHP or CHOP for 6–8 cycles (q3wk). Randomization will be stratified by ALK+ sALCL vs other histologic subtypes and IPI score (0–1, 2–3, or 4–5). The target proportion of pts with a diagnosis of sALCL will be 75%. The primary objective is to compare progression-free survival (PFS) between the 2 treatment arms as determined by an independent review facility (IRF). Secondary objectives include comparisons of PFS per IRF in sALCL patients, safety, overall survival, and complete remission rate between the 2 arms. After completion of treatment, pts will be followed for disease progression, medical resource utilization, quality of life, and survival. Post-treatment stem cell transplant is permitted. Efficacy assessments will use the Revised Response Criteria for Malignant Lymphoma (Cheson 2007). CT and PET scans will be performed at baseline, after Cycle 4, and after the completion of treatment. CT scans will also be performed at regular intervals during follow-up until disease progression, death, or analysis of the primary endpoint. Safety assessments will occur throughout the study until 30 days after last dose of study treatment. Enrollment for this global trial began in early 2013. Clinical trial information: NCT01777152.
Noise Pollution
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intracoronary thrombolysis to abort heart attacks: wave of the future?
Authors: E. R. Gonzalez
Journal: JAMA (1981)

The audience emitted a collective gasp. On a movie screen in front of them, a nasty clot was high-tailing it through a coronary artery. Within about 30 s, the clot had dissolved. The man who had caused the clot lysis—William Ganz, MD, professor of medicine at UCLA and senior research scientist, Cedars-Sinai Medical Center, Los Angeles—modestly denied "planning" the event that his extraordinary film footage captured so that it would occur at that precise moment. There is no clinical marker for mobilization of the thrombus, he said, but generally it<i>will</i>get going if you infuse a thrombolytic agent as close to its exact location as possible. Ganz and colleagues use a standard catheter through which they advance a special soft catheter (diameter, 0.022 in) to the site of the clot. They then infuse Thrombolysin (a combination of streptokinase and plasminogen) through the special catheter at a dosage of 2,000
Percutaneous Cholangiography
Authors: R. Burkitt
Journal: BMJ (1967)

In 1965 routine virus studies in the Blackburn group of hospitals showed that not only polio virus, both wild and vaccine strains, were isolated but also the following entero- viruses: Coxsackie types A5, A9, B3, B4, and B5.E.C.H.O.types 3, 6, 7, 8, 15, and 22.Most of these cases occurred during July, August, and September.Infants infected with rubella in utero harbour the virus after they are born, and it can be isolated and even infect other susceptible individuals.We felt it worth while, therefore, to see if we could culture any enteroviruses from foetuses, stillbirths, and neonatal deaths where the first trimester of pregnancy coincided in whole or in part with the enterovirus outbreak.This was done in 23 cases and selection was random.In one case faeces only of a child who survived with an abnormality were examined.Investigation was not confined to infants who were con- genitally abnormal.Brain, lungs, faeces, and placenta were examined by conventional methods, being inoculated into monkey-kidney, human- amnion, and Hela-cell cultures.The foetal tissues and placentas were examined for histological changes.All results were negative except for one case.This was a full-term stillborn infant who had shown foetal distress.E.C.H.O.virus type 3 was isolated but the histology was negative.The mother's blood was examined in November 1966 and no E.C.H.O.antibodies were demonstrated.
Correction
Journal: Circulation Research (2015)

The Circulation Research article by Keith and Bolli (“String Theory” of c-kitpos Cardiac Cells: A New Paradigm Regarding the Nature of These Cells That May Reconcile Apparently Discrepant Results. Circ Res. 2015:116:1216-1230. doi: 10.1161/CIRCRESAHA.116.305557) states that van Berlo et al (2014) observed that large numbers of fibroblasts and adventitial cells, some smooth muscle and endothelial cells, and rare cardiomyocytes originated from c-kit positive progenitors. However, van Berlo et al reported that only occasional fibroblasts and adventitial cells derived from c-kit positive progenitors in their studies. Accordingly, the review has been corrected to indicate that van Berlo et al (2014) observed that large numbers of endothelial cells, with some smooth muscle cells and fibroblasts, and more rarely cardiomyocytes, originated from c-kit positive progenitors in their murine model. The authors apologize for this error, and the error has been noted and corrected in the online version of the article, which is available at http://circres.ahajournals.org/content/116/7/1216.full (
Hirsutism.
Authors: G S Conway, H S Jacobs
Journal: BMJ (1990)

][32][33][34][35][36][37] The results have been conflicting and difficult to interpret because the changes may have been due to alterations in the sensitivity of the assay.35Nevertheless, it does seem that hormone concentrations remain within the normal range after vasectomy, though seasonal variations seem to be lost.38Clearly, then, we need to learn much more about the effect of vasectomy on seminiferous tubules.We need to know about the possibility of different forms of testicular change in different people, predisposing factors such as a history of orchitis or a personal or family history of autoimmune disease, and the relation between the formation of sperm granulomas and testicular changes in man.Most importantly, however, we need further studies to define the risk of testicular cancer after vasectomy and to identify causal factors.
Tetrahydroaminoacridine-induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspensions
Authors: M Fariss
Journal: Hepatology (1994)

Tacrine (tetrahydroaminoacridine) is currently the only drug approved for the treatment of Alzheimer's disease. Unfortunately, tetrahydroaminoacridine therapy is often limited by this drug's propensity to induce reversible hepatotoxicity. Using suspensions of freshly isolated rat hepatocytes, we investigated the mechanism of tetrahydroaminoacridine cytotoxicity by examining the effect of tetrahydroaminoacridine on hepatocyte viability, protein synthesis, protein, DNA and RNA levels and ultrastructure. Our experimental findings support the explanation that tetrahydroaminoacridine-induced hepatotoxicity results from tetrahydroaminoacridine's adverse effect on protein synthesis and ribosomal structure and function. We found that viable, tetrahydroaminoacridine-treated hepatocytes (1.0 to 2.0 mmol/L or 118 to 235 micrograms/10(6) cells) demonstrated a dose-dependent and dramatic aggregation of ribosomes on endoplasmic reticulum as well as the aggregation of other nucleic acids found in the nucleus (chromatin) and in mitochondria. These electron microscopy data suggest that tetrahydroaminoacridine treatment results in severe ribosomal dysfunction. This was confirmed by the observed rapid loss of cellular RNA content (but not DNA or protein) and the rapid and complete inhibition of protein synthesis in tetrahydroaminoacridine-treated cells (lowest concentration tested was 0.5 mmol/L or 58 micrograms/10(6) cells). Thus tetrahydroaminoacridine treatment appears to aggregate hepatocellular nucleic acids, and in doing so adversely affects ribosomal function and protein synthesis. We propose that these adverse effects of exposure to tetrahydroaminoacridine are responsible for tetrahydroaminoacridine-induced hepatotoxicity.